Cerevance’s solengepras hits Phase 3 targets, while Australian trial shows anti-inflammatory promise
Cerevance announced that its non-dopaminergic drug solengepras met its primary endpoint in a Phase 3 trial, significantly reducing 'off time' for Parkinson’s patients. The company plans to seek FDA approval. Separately, an Australian-led trial reported that SNT-4728 reduced brain inflammation in high-risk individuals, offering a potential preventive approach.
